FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Geron ESC therapy heals spinal cord damage in rats

Geron's clinical stage embryonic stem cell treatment was used to restore the limb function of rats--a preclinical development that may allow the biotech company to expand the scope of its trial to include cervical damage.

Geron obtained the FDA's first approval to test an ESC treatment in humans. But regulators restricted the investigation to thoracic spinal cord damage. Cervical damage was excluded because it had yet to be tested in animals. Cases involving spinal cord injuries are about evenly split between cervical and thoracic damage.

"People with cervical damage often have lost or impaired limb movement and bowel, bladder or sexual function, and currently there's no effective treatment. It's a challenging existence," said UC Irvine scientist Hans Keirstead, a primary author of the study. "What our therapy did to injured rodents is phenomenal. If we see even a fraction of that benefit in humans, it will be nothing short of a home run."

The treatment relies on ESCs that are transformed into spinal cord cells that create myelin, nerve fiber insulation that is damaged in an injury, which can lead to paralysis.

- check out the UCI release

Related Articles:
Geron shares jump on GE stem cell pact
Geron offers reassurance on its ESC safety record


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Research Email Newsletter:
Comments (1) | Post a comment
More stories about preclinical   Human Embryonic Stem Cell   Geron  

Comments

I found your post really interesting and it has really improved my knowledge on the matter.
http://www.youtube.com/watch?v=EyuUyN5RVTI

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.